Mani Foroohar

Moderna Gets A 'Booster' Shot: Why Stock Is Up Nearly 7% Today
Moderna Rallies After Q4 Earnings: What 2 Analysts Have To Say About COVID-19 Stock
Intellia Therapeutics Analyst Doubles Price Target: What You Need To Know
Moderna Rallies After Q4 Earnings: What 2 Analysts Have To Say About COVID-19 Stock
Intellia Therapeutics Analyst Doubles Price Target: What You Need To Know
Moderna Analysts Discuss Adcom Verdict, Distribution And Commercialization Of Coronavirus Vaccine
Moderna Analysts On Positive Coronavirus Vaccine Data, Revenue Potential

Mani Foroohar Recent News

Moderna Analyst On 4 Coronavirus Vaccine Program Risks
Moderna Inc (NASDAQ: MRNA) is one of the frontrunners in a crowded race to develop a vaccine against the novel coronavirus.
3 Moderna Analyst Takes On The Coronavirus Vaccine Developer's Pipeline
Coronavirus vaccine developer Moderna Inc (NASDAQ: MRNA) held a virtual R&D event Thursday, showcasing its portfolio and key therapeutics areas.
AstraZeneca's Coronavirus Vaccine Setback 'Mixed Blessing' For Moderna: Analyst
Moderna Inc (NASDAQ: MRNA) shares, which shed over 13% Tuesday on an analyst downgrade, are reversing course — with a competitor'
Moderna Analyst Downgrades COVID-19 Vaccine Developer, Sees 'Changing Competitive Environment'
Competitive pressure could impair Moderna Inc's (NASDAQ: MRNA) ability to take advantage of its strong position in the coronavirus vaccine race, according to an analyst at SVB Leerink.
2 Moderna Analysts On Chances Of COVID-19 Vaccine Approval, Upcoming Catalysts
Two Moderna Inc (NASDAQ: MRNA) analysts issued snapshots this week on the progress of the company's coronavirus vaccine program.
Moderna Analysts Say COVID-19 Vaccine Contract Reflects Pricing Risk, Shows Ability To Scale
After hinting at ongoing negotiations for larger vaccine deals on its earnings call, Moderna Inc (NASDAQ: MRNA) said late Tuesday that it signed an agreemen
Moderna Posts Q2 Beat, Reportedly Closes In On Coronavirus Vaccine Deal With Swiss Government
Moderna Inc (NASDAQ: MRNA) shares were moving to the downside Wednesday despite the coronavirus vaccine developer reporting forecast-beating second-quarter results and reports of a potential deal with the Sw
Moderna Shares Rebound As Biopharma Starts Late-Stage Coronavirus Vaccine Trial, Snags More Funding
Close on the heels of announcing additional BARDA funding for its coronavirus vaccine candidate mRNA-1273, Moderna Inc (NASDAQ: MRNA) said Monday tha
Moderna Analyst Says Odds Are Good For COVID-19 Vaccine Approval, But Valuation Overcooked
Moderna Inc's (NASDAQ: MRNA) coronavirus vaccine in development — mRNA-1273 — continues to inspire confidence among sell-side anal
Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns'